No Data
2024 Annual Results Forecast
ZhiXiang JinTai (688443.SH): The new drug application for Silevimab injection has been accepted.
On January 14, Gelonghui reported that Zhixiang Jintai (688443.SH) announced that its SLEWEI monoclonal antibody injection (GR1801 injection) for passive immunity indications after suspected rabies virus exposure in adults has reached the primary efficacy endpoint in the Phase III clinical trial. The company has submitted a new drug marketing application to the National Medical Products Administration (NMPA) Drug Evaluation Center (CDE) and it has been accepted. The SLEWEI monoclonal antibody injection is a recombinant fully human anti-rabies virus (Rabies Virus, RABV) bispecific antibody independently developed by the company, and its registration classification is for therapeutic use.
Kaiyuan Securities: Each subtype of hematological tumors has the potential to hatch "heavyweight bomb" drugs. Pay attention to Innovative Drugs companies.
The subtype of blood tumors is less aggressive with a longer treatment cycle, generally requiring long-term medication. Patients have relatively high viscosity and the potential for the emergence of "blockbuster" drugs.
Zhixiang Jintai (688443.SH): Liu Zhigang elected as Director.
Gelonghui reported on December 24 that Zhixiang Jintai (688443.SH) announced that on December 24, 2024, the company will hold the first meeting of the second Board of Directors, which reviewed and approved the "Proposal on Election of the Chairman of the Second Board of Directors of the Company". All directors unanimously agreed to elect Mr. Liu Zhigang as the Chairman of the Company's second Board of Directors for a term of three years, the same as thisBoard's term.
Despite Lacking Profits Chongqing Genrix Biopharmaceutical (SHSE:688443) Seems To Be On Top Of Its Debt
Zhixiang Jintai: Third Quarter Report 2024
No Data
